For now all small Bios are getting slammed down! As strongly as I feel
that only a BP will be able to optimize sales of Vascepa, for now the strategy
is to GIA and/or partner to build up revenues. If Denner plans to sell the company
my guess is he will bring up Sarissa's stake closer to 20%. Before any reasonable
BO can be announced he would have to get the share price up to a much higher
level. Meanwhile, we wait to see what can be salvaged from the US, how many
more countries in Europe AMRN can get for reimbursement, and, see what China
may bring. Of course we all hope that Denner will bring in more institutional ownership.
Watching this play out would be much more fun if the stock price were moving up!